| Bioactivity | Povorcitinib is a potent and selective inhibitor of JAK1. Povorcitinib has the potential for the research of disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) (extracted from patent WO2021076124A1)[1]. | ||||||||||||
| Target | JAK1 | ||||||||||||
| Name | Povorcitinib | ||||||||||||
| CAS | 1637677-22-5 | ||||||||||||
| Formula | C23H22F5N7O | ||||||||||||
| Molar Mass | 507.46 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Paul Smith, et al. Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp). Patent WO2021076124A1. |
Povorcitinib
CAS: 1637677-22-5 F: C23H22F5N7O W: 507.46
Povorcitinib is a potent and selective inhibitor of JAK1. Povorcitinib has the potential for the research of diseas
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.